• Blog
  • Focal Segmental Glomerulosclerosis Fsgs Market Report

    Focal Segmental Glomerulosclerosis Fsgs Market Report

    Focal Segmental Glomerulosclerosis Fsgs Market Report
    Report code - SR1784 Delivery - 2 Weeks
    Get Free Sample |
    Focal Segmental Glomerulosclerosis (FSGS) Market Size, Share & Forecast Analysis (2021 See more...

    Market Insights

    The Focal Segmental Glomerulosclerosis (FSGS) Market is estimated to grow from USD 9.4 billion in 2020 to USD 15.2 billion by 2026 at a healthy CAGR of 8.4% during the forecast period.

    Focal Segmental Glomerulosclerosis (FSGS) Market- Research Scope

    Base Year of Study

    2020

    Trend Period

    2015-2019

    Forecast Period

    2021-2026

    Market Size in 2020

    US$ 9.4 billion

    Market Size in 2026

    US$ 15.2 billion

    Market Growth (2021-2026)

    8.4% CAGR

     

    Figure: Focal Segmental Glomerulosclerosis (FSGS) Market Size, 2020-2026 (USD Billion)

    Wish to get a free sample? Register Here

    What is Focal Segmental Glomerulosclerosis (FSGS)?

    Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease which affects the kidney's filtering system and results in serious scarring as well as end stage renal disease. The focal segmental glomerulosclerosis is the progressive scarring of the kidney that is featured by proteinuria. It is one of the rare diseases that affects kidney function by damaging and attacking the glomeruli. This disease is characterized by kidney defects by obesity, birth, sickle cell anemia, obstructive sleep apnea, and viruses such as HIV, among others.

    Covid-19 Impact Analysis

    The COVID-19 pandemic has moderately affected the Focal Segmental Glomerulosclerosis (FSGS) industry. The rapid spread of COVID-19 has resulted in several thousands of hospital admissions. The focus of healthcare professionals has been shifted toward the treatment of COVID-19-infected patients, which affected the treatment of non-emergency medical conditions, amid the pandemic.

    Key Players

    Key players operating in the global Focal Segmental Glomerulosclerosis (FSGS) Market are-

    • GlaxoSmithKline plc. (UK)
    • Novartis AG (Switzerland)
    • Variant Pharmaceuticals, Inc. (US)
    • ChemoCentryx, Inc. (US)
    • Retrophin, Inc. (US)
    • AbbVie, Inc. (US)
    • Pfizer, Inc. (US)
    • AstraZeneca plc. (UK)
    • Sanofi S.A (France)
    • Teva Pharmaceutical Industries Ltd. (Israel)

    Market Dynamics

    The Focal Segmental Glomerulosclerosis (FSGS) market is majorly driven by growing focus towards rare diseases, rising disease burden, and growing R&D investments. The prevalence of FSGS is comparatively high when compared to other glomerular diseases. Also, surging support by non-government organizations to spread awareness regarding the rare disease as well as increasing allocation towards research on such rare diseases, further augments the market growth.

    Segments Analysis

    Disease Trends

    Based on Disease, the Focal Segmental Glomerulosclerosis (FSGS) market has been classified into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. The oxygenators segment accounted for the largest market in 2020. Primary focal segmental glomerulosclerosis is a type of focal segmental glomerulosclerosis disease without an obvious or known cause. Increasing awareness about the disease and its management is likely to bolster the market growth.

    Regional Trends

    By region, the North America Focal Segmental Glomerulosclerosis (FSGS) market accounted the highest share in 2020 and is expected to grow at a robust CAGR during the review period. The Focal Segmental Glomerulosclerosis (FSGS) market growth is mainly attributed to large presence of a properly structured health care sector and easy availability of reimbursement policies with broader coverage.

    The Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) market is expected to grow at the healthy CAGR during the review period due to surge in the healthcare expenditure by the government to improve healthcare facilities. Also, significant growth in the healthcare sector, rising diagnosis rate of focal segmental glomerulosclerosis, and easy availability of drugs & dialysis at a lower price, further bolsters the regional market growth.

    Critical Questions Answered in the Report

    This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Focal Segmental Glomerulosclerosis (FSGS) market. The historic years considered for the study are 2016-2019, base year is 2020, estimated year is 2021, and forecast period is 2022-2026. Following are the critical questions answered in the report.

    • What are the key trends in the global Focal Segmental Glomerulosclerosis (FSGS) market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in next five years?
    • What is the impact of COVID-19 on global Focal Segmental Glomerulosclerosis (FSGS) market?
    • What are the key strategies adopted by the major vendors to lead in the global Focal Segmental Glomerulosclerosis (FSGS) market?
    • What is the market share of the top vendors?

    Target Audience

    The target audience of Focal Segmental Glomerulosclerosis (FSGS) Market includes-

    • Focal Segmental Glomerulosclerosis (FSGS) Vendors
    • Focal Segmental Glomerulosclerosis (FSGS) Manufacturers
    • Focal Segmental Glomerulosclerosis (FSGS) Distributors
    • Organizations
    • Government Bodies.

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The Global Focal Segmental Glomerulosclerosis (FSGS) Market is estimated to grow from USD 9.4 billion in 2020 to USD 15.2 billion by 2026 at a healthy CAGR of 8.4% during the forecast period.

    Key players operating in the global Focal Segmental Glomerulosclerosis (FSGS) Market are- GlaxoSmithKline plc. (UK), Novartis AG (Switzerland), Variant Pharmaceuticals, Inc. (US), ChemoCentryx, Inc. (US), Retrophin, Inc. (US), AbbVie, Inc. (US), Pfizer, Inc. (US), AstraZeneca plc. (UK), Sanofi S.A (France), Teva Pharmaceutical Industries Ltd. (Israel)

    The Focal Segmental Glomerulosclerosis (FSGS) market is majorly driven by growing focus towards rare diseases, rising disease burden, and growing R&D investments.

    North America Focal Segmental Glomerulosclerosis (FSGS) market accounted the highest share in 2020 and is expected to grow at a robust CAGR during the review period.

    The target audience of Focal Segmental Glomerulosclerosis (FSGS) Market includes- Focal Segmental Glomerulosclerosis (FSGS) Vendors, Focal Segmental Glomerulosclerosis (FSGS) Manufacturers, Focal Segmental Glomerulosclerosis (FSGS) Distributors, Organizations, Government Bodies.